C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 84 filers reported holding C4 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $288,994 | -32.4% | 155,373 | 0.0% | 0.00% | – |
| Q2 2023 | $427,276 | -82.4% | 155,373 | -79.9% | 0.00% | – |
| Q1 2023 | $2,431,054 | -91.6% | 774,221 | -84.2% | 0.00% | -100.0% |
| Q4 2022 | $28,881,644 | +67.9% | 4,895,194 | +149.5% | 0.00% | 0.0% |
| Q3 2022 | $17,205,000 | +218.5% | 1,961,812 | +173.8% | 0.00% | – |
| Q2 2022 | $5,402,000 | -90.0% | 716,443 | -67.8% | 0.00% | -100.0% |
| Q1 2022 | $54,045,000 | +5.6% | 2,227,759 | +40.1% | 0.00% | +50.0% |
| Q4 2021 | $51,190,000 | -30.9% | 1,589,753 | -4.2% | 0.00% | -50.0% |
| Q3 2021 | $74,108,000 | +42.9% | 1,658,630 | +21.0% | 0.00% | +33.3% |
| Q2 2021 | $51,864,000 | +62.4% | 1,370,622 | +58.8% | 0.00% | +50.0% |
| Q1 2021 | $31,931,000 | +483.6% | 863,233 | +422.8% | 0.00% | – |
| Q4 2020 | $5,471,000 | – | 165,131 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $14,402,000 | 1.72% |
| Soleus Capital Management, L.P. | 1,441,513 | $12,642,000 | 1.72% |
| Nextech Invest Ltd. | 375,857 | $3,296,000 | 1.06% |
| RTW INVESTMENTS, LP | 2,819,472 | $24,727,000 | 0.57% |
| ArrowMark Colorado Holdings LLC | 5,091,975 | $44,657,000 | 0.55% |
| WASATCH ADVISORS LP | 5,934,476 | $52,045,000 | 0.36% |
| HARBOR CAPITAL ADVISORS, INC. | 25,470 | $223,000 | 0.20% |
| Perceptive Advisors | 766,231 | $6,720,000 | 0.20% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 606,721 | $5,321,000 | 0.08% |
| Virtus ETF Advisers LLC | 19,305 | $169,000 | 0.07% |